Hopital Saint-Eloi

Montpellier 34295 Cedex 5

4 studies enrolling now · 28 studies all time

What they study most

Acute Kidney Injury, B-cell Malignancies, Chronic Hepatitis C, Chronic Lymphocytic Leukemia, Colitis, Ulcerative, Hepatitis C, Chronic, High-risk Large B-cell Lymphoma (LBCL), Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma. Non-Hodgkin, Malignant Melanoma, Melanoma

Studies at this site

• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma — Running, not enrolling
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — Running, not enrolling
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma — Running, not enrolling
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies — Stopped early
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma — Completed
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) — Stopped early
• A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma — Completed
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury — Stopped early
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed
• A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Completed
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL — Completed
• A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies — Completed
• Trial of Dacarbazine With or Without Genasense in Advanced Melanoma — Completed
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma — Completed